By: Ruairi Mckenzie
Blackrock Neurotech, a leader in brain-computer interface (BCI) device design, recently has announced a collaboration with Venice, CA-based software developer AE Studio. Blackrock’s MoveAgain BCI was recently granted breakthrough device designation by the Food and Drug Administration (FDA). AE Studio will bring their expertise to the software powering MoveAgain, enhancing the system’s machine learning models and algorithms to improve usage for patients.